Literature DB >> 30126028

High- and low-dose oral immunotherapy similarly suppress pro-allergic cytokines and basophil activation in young children.

Michael Kulis1,2, Xiaohong Yue1,2, Rishu Guo1,2, Huamei Zhang1,2, Kelly Orgel1,2, Ping Ye1,2, Quefeng Li3, Yutong Liu3, Edwin Kim1,2, Arvil Wesley Burks1,2, Brian P Vickery4.   

Abstract

BACKGROUND: Mechanisms underlying oral immunotherapy (OIT) are unclear and the effects on immune cells at varying maintenance doses are unknown.
OBJECTIVE: We aimed to determine the immunologic changes caused by peanut OIT in preschool aged children and determine the effect on these immune responses in groups ingesting low or high-dose peanut OIT (300 mg or 3000 mg, respectively) as maintenance therapy.
METHODS: Blood was drawn at several time-points throughout the OIT protocol and PBMCs isolated and cultured with peanut antigens. Secreted cytokines were quantified via multiplex assay, whereas Treg and peanut-responsive CD4 T cells were studied with flow cytometry. Basophil activation assays were also conducted.
RESULTS: Th2-, Th1-, Th9- and Tr1-type cytokines decreased over the course of OIT in groups on high- and low-dose OIT. There were no significant differences detected in cytokine changes between the high- and low-dose groups. The initial increase in both the number of peanut-responsive CD4 T cells and the number of Tregs was transient and no significant differences were found between groups. Basophil activation following peanut stimulation was decreased over the course of OIT and associated with increased peanut-IgG4/IgE ratios. No differences were found between high- and low-dose groups in basophil activation at the time of desensitization or sustained unresponsiveness oral food challenges. CONCLUSIONS AND CLINICAL RELEVANCE: Peanut OIT leads to decreases in pro-allergic cytokines, including IL-5, IL-13, and IL-9 and decreased basophil activation. No differences in T cell or basophil responses were found between subjects on low or high-dose maintenance OIT, which has implications for clinical dosing strategies.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  basophil; food allergy; oral immunotherapy; peanut allergy; regulatory T cell

Year:  2018        PMID: 30126028      PMCID: PMC6353702          DOI: 10.1111/cea.13256

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  23 in total

1.  Successful immunotherapy induces previously unidentified allergen-specific CD4+ T-cell subsets.

Authors:  John F Ryan; Rachel Hovde; Jacob Glanville; Shu-Chen Lyu; Xuhuai Ji; Sheena Gupta; Robert J Tibshirani; David C Jay; Scott D Boyd; R Sharon Chinthrajah; Mark M Davis; Stephen J Galli; Holden T Maecker; Kari C Nadeau
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-25       Impact factor: 11.205

2.  Evidence of pathway-specific basophil anergy induced by peanut oral immunotherapy in peanut-allergic children.

Authors:  A Thyagarajan; S M Jones; A Calatroni; L Pons; M Kulis; C S Woo; M Kamalakannan; B P Vickery; A M Scurlock; A Wesley Burks; W G Shreffler
Journal:  Clin Exp Allergy       Date:  2012-08       Impact factor: 5.018

3.  Specific epicutaneous immunotherapy prevents sensitization to new allergens in a murine model.

Authors:  Lucie Mondoulet; Vincent Dioszeghy; Emilie Puteaux; Mélanie Ligouis; Véronique Dhelft; Camille Plaquet; Christophe Dupont; Pierre-Henri Benhamou
Journal:  J Allergy Clin Immunol       Date:  2015-01-09       Impact factor: 10.793

4.  A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy.

Authors:  Satya D Narisety; Pamela A Frischmeyer-Guerrerio; Corinne A Keet; Mark Gorelik; John Schroeder; Robert G Hamilton; Robert A Wood
Journal:  J Allergy Clin Immunol       Date:  2014-12-18       Impact factor: 10.793

5.  Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective.

Authors:  Brian P Vickery; Jelena P Berglund; Caitlin M Burk; Jason P Fine; Edwin H Kim; Jung In Kim; Corinne A Keet; Michael Kulis; Kelly G Orgel; Rishu Guo; Pamela H Steele; Yamini V Virkud; Ping Ye; Benjamin L Wright; Robert A Wood; A Wesley Burks
Journal:  J Allergy Clin Immunol       Date:  2016-08-10       Impact factor: 10.793

6.  Clinical efficacy and immune regulation with peanut oral immunotherapy.

Authors:  Stacie M Jones; Laurent Pons; Joseph L Roberts; Amy M Scurlock; Tamara T Perry; Mike Kulis; Wayne G Shreffler; Pamela Steele; Karen A Henry; Margaret Adair; James M Francis; Stephen Durham; Brian P Vickery; Xiaoping Zhong; A Wesley Burks
Journal:  J Allergy Clin Immunol       Date:  2009-07-03       Impact factor: 10.793

Review 7.  Molecular and cellular mechanisms of food allergy and food tolerance.

Authors:  R Sharon Chinthrajah; Joseph D Hernandez; Scott D Boyd; Stephen J Galli; Kari C Nadeau
Journal:  J Allergy Clin Immunol       Date:  2016-04       Impact factor: 10.793

8.  IL-9 is a key component of memory TH cell peanut-specific responses from children with peanut allergy.

Authors:  Helen A Brough; David J Cousins; Alina Munteanu; Yuen Fei Wong; Asha Sudra; Kerry Makinson; Alick C Stephens; Matthew Arno; Liviu Ciortuz; Gideon Lack; Victor Turcanu
Journal:  J Allergy Clin Immunol       Date:  2014-08-10       Impact factor: 10.793

9.  Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial.

Authors:  Katherine Anagnostou; Sabita Islam; Yvonne King; Loraine Foley; Laura Pasea; Simon Bond; Chris Palmer; John Deighton; Pamela Ewan; Andrew Clark
Journal:  Lancet       Date:  2014-01-30       Impact factor: 79.321

10.  Elevated antigen-driven IL-9 responses are prominent in peanut allergic humans.

Authors:  Jungang Xie; Larisa C Lotoski; Rishma Chooniedass; Ruey-Chyi Su; F Estelle R Simons; Joel Liem; Allan B Becker; Jude Uzonna; Kent T HayGlass
Journal:  PLoS One       Date:  2012-10-11       Impact factor: 3.240

View more
  19 in total

Review 1.  Evolution of Immune Responses in Food Immunotherapy.

Authors:  Johanna M Smeekens; Michael D Kulis
Journal:  Immunol Allergy Clin North Am       Date:  2019-11-06       Impact factor: 3.479

2.  Phase 2a randomized, placebo-controlled study of anti-IL-33 in peanut allergy.

Authors:  Sharon Chinthrajah; Shu Cao; Cherie Liu; Shu-Chen Lyu; Sayantani B Sindher; Andrew Long; Vanitha Sampath; Daniel Petroni; Marco Londei; Kari C Nadeau
Journal:  JCI Insight       Date:  2019-11-14

3.  Sustained successful peanut oral immunotherapy associated with low basophil activation and peanut-specific IgE.

Authors:  Mindy Tsai; Kaori Mukai; R Sharon Chinthrajah; Kari C Nadeau; Stephen J Galli
Journal:  J Allergy Clin Immunol       Date:  2019-12-02       Impact factor: 10.793

Review 4.  Microfluidic methods for precision diagnostics in food allergy.

Authors:  Nicolas Castaño; Seth C Cordts; Kari C Nadeau; Mindy Tsai; Stephen J Galli; Sindy K Y Tang
Journal:  Biomicrofluidics       Date:  2020-04-03       Impact factor: 2.800

Review 5.  Biomarkers in Food Allergy Immunotherapy.

Authors:  LaKeya C Hardy; Johanna M Smeekens; Michael D Kulis
Journal:  Curr Allergy Asthma Rep       Date:  2019-12-04       Impact factor: 4.806

6.  Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study.

Authors:  R Sharon Chinthrajah; Natasha Purington; Sandra Andorf; Andrew Long; Katherine L O'Laughlin; Shu Chen Lyu; Monali Manohar; Scott D Boyd; Robert Tibshirani; Holden Maecker; Marshall Plaut; Kaori Mukai; Mindy Tsai; Manisha Desai; Stephen J Galli; Kari C Nadeau
Journal:  Lancet       Date:  2019-09-12       Impact factor: 79.321

Review 7.  Emerging Food Allergy Biomarkers.

Authors:  Sarita U Patil; Supinda Bunyavanich; M Cecilia Berin
Journal:  J Allergy Clin Immunol Pract       Date:  2020-09

Review 8.  Mechanisms of oral immunotherapy.

Authors:  Suzanne M Barshow; Michael D Kulis; A Wesley Burks; Edwin H Kim
Journal:  Clin Exp Allergy       Date:  2021-01-20       Impact factor: 5.401

9.  A randomized trial of the acceptability of a daily multi-allergen food supplement for infants.

Authors:  Jane L Holl; Lucy A Bilaver; Daniel J Finn; Kay Savio
Journal:  Pediatr Allergy Immunol       Date:  2020-02-20       Impact factor: 6.377

10.  Oral immunotherapy for multiple foods in a pediatric allergy clinic setting.

Authors:  Amy A Eapen; William J Lavery; Jaweriah S Siddiqui; Michelle B Lierl
Journal:  Ann Allergy Asthma Immunol       Date:  2019-09-06       Impact factor: 6.347

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.